## Contents

### Part I  Biology

1. **Update on the Biology of Myeloproliferative Neoplasms**  
   Robert Kralovics  
   3

2. **Do We Need Biological Studies for Patient Management?**  
   Moosa Qureshi and Claire Harrison  
   11

### Part II  General Issues in the Management of MPNs

3. **Critical Issues About the Diagnosis of MPNs: Bone Marrow Histopathology**  
   Jürgen Thiele and Hans Michael Kvasnicka  
   19

4. **Critical Issues About the Diagnosis of Myeloproliferative Neoplasms: World Health Organization Classification**  
   Mary Frances McMullin  
   37

5. **Patient’s Information and Examinations Needed Before Planning Therapy in the Myeloproliferative Neoplasms**  
   Francisco Cervantes and Juan-Carlos Hernández-Boluda  
   47

6. **Mechanisms of Thrombogenesis**  
   Anna Falanga, Laura Russo, and Marina Marchetti  
   57

### Part III  Specific Issues of Treatment in PV and ET

7. **Risk Classification**  
   Guido Finazzi  
   71

8. **Goal of Therapy and Monitoring the Response in Polycythemia Vera and Essential Thrombocythemia**  
   Jean-Jacques Kiladjian  
   85

9. **First-Line Therapy and Special Issues Management in Polycythemia Vera and Essential Thrombocythemia**  
   Tiziano Barbui  
   93

10. **Primary and Secondary Antithrombotic Prophylaxis**  
    Leonardo Di Gennaro and Raffaele Landolfi  
    105
11 Polycythemia Vera and Essential Thrombocythemia: When to Change Therapy – Second-Line Options 119
Alessandro M. Vannucchi

12 Blastic Transformation of BCR-ABL-Negative Myeloproliferative Neoplasms 131
Madappa N. Kundrada, Raoul Tibes, and Ruben A. Mesa

Part IV Treatment of PMF

13 Current Clinical Needs 149
Giovanni Barosi

14 Risk Stratification in PMF 163
Francesco Passamonti

15 Nontransplant Treatment Options for Myelofibrosis: How to Treat Anemia, Splenomegaly, Constitutional Symptoms, and Extramedullary Disease 177
Ayalew Tefferi

16 Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis 187
Nicolaus Kröger

Part V Research Issues and Perspectives

17 A Critical Review of the Role and Limitations of JAK Inhibitors in Myelofibrosis Therapy 203
Animesh Pardanani

18 Ongoing Clinical Trials in Myeloproliferative Neoplasms 215
Fabio P.S. Santos and Srdan Verstovsek

Index 233
Myeloproliferative Neoplasms
Critical Concepts and Management
(Eds.) T. Barbi; A. Tefferi
2012, VIII, 240 p. 22 illus. 13 in color., Hardcover
ISBN: 978-3-642-24988-4